Furthermore, using in vivo tumor models established by xenografting HepG2-hFAP, U87, and primary hepatic carcinoma cell lines into mice, we validated the antitumor efficacy of FAP/IL-15 CAR-T therapy. This evidence concerns the gene FAP and hepatocellular carcinoma.